1. Home
  2. GNL vs NTLA Comparison

GNL vs NTLA Comparison

Compare GNL & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNL
  • NTLA
  • Stock Information
  • Founded
  • GNL 2011
  • NTLA 2014
  • Country
  • GNL United States
  • NTLA United States
  • Employees
  • GNL N/A
  • NTLA N/A
  • Industry
  • GNL Real Estate Investment Trusts
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • GNL Real Estate
  • NTLA Health Care
  • Exchange
  • GNL Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • GNL 1.7B
  • NTLA 794.5M
  • IPO Year
  • GNL N/A
  • NTLA 2016
  • Fundamental
  • Price
  • GNL $7.64
  • NTLA $9.76
  • Analyst Decision
  • GNL Buy
  • NTLA Buy
  • Analyst Count
  • GNL 4
  • NTLA 19
  • Target Price
  • GNL $9.50
  • NTLA $35.11
  • AVG Volume (30 Days)
  • GNL 2.1M
  • NTLA 4.8M
  • Earning Date
  • GNL 08-05-2025
  • NTLA 08-07-2025
  • Dividend Yield
  • GNL 9.95%
  • NTLA N/A
  • EPS Growth
  • GNL N/A
  • NTLA N/A
  • EPS
  • GNL N/A
  • NTLA N/A
  • Revenue
  • GNL $789,545,000.00
  • NTLA $45,569,000.00
  • Revenue This Year
  • GNL N/A
  • NTLA N/A
  • Revenue Next Year
  • GNL N/A
  • NTLA N/A
  • P/E Ratio
  • GNL N/A
  • NTLA N/A
  • Revenue Growth
  • GNL 38.85
  • NTLA N/A
  • 52 Week Low
  • GNL $6.51
  • NTLA $5.90
  • 52 Week High
  • GNL $9.11
  • NTLA $28.18
  • Technical
  • Relative Strength Index (RSI)
  • GNL 51.00
  • NTLA 56.49
  • Support Level
  • GNL $7.32
  • NTLA $8.88
  • Resistance Level
  • GNL $7.66
  • NTLA $10.14
  • Average True Range (ATR)
  • GNL 0.16
  • NTLA 0.58
  • MACD
  • GNL 0.01
  • NTLA 0.05
  • Stochastic Oscillator
  • GNL 58.91
  • NTLA 52.78

About GNL Global Net Lease Inc.

Global Net Lease Inc is a real estate investment trust that manages a globally diversified portfolio of commercial real estate properties. The company is engaged in the ownership, management, operating, lease, acquisition, investment, and sale of the portfolio assets. Its segments include Industrial & Distribution; Multi-Tenant Retail; Single-Tenant Retail; and office. The company derives maximum revenue from industrial and distribution segment. The company geographically operates in Unites States, United Kingdom, Canada and Europe.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: